查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球神经诊断学市场 - 2023-2030年
市场调查报告书
商品编码
1297822

全球神经诊断学市场 - 2023-2030年

Global Neurodiagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球神经诊断市场在2022年达到75亿美元，预计到2030年将见证有利可图的增长，达到132亿美元。在2023-2030年的预测期内，全球神经诊断市场预计将呈现7.6%的复合增长率。

神经诊断测试可以在早期阶段发现神经系统的异常，甚至在症状变得明显之前。这种早期检测允许及时干预和治疗，有可能防止病情的进一步损害或发展。神经诊断可以帮助区分可能具有类似症状的不同神经系统疾病。

阿尔茨海默病、肌萎缩性脊髓侧索硬化症、亨廷顿病、帕金森病和脊髓性肌肉萎缩症等神经系统疾病的发病率上升，将在预测期内推动对神经诊断产品的需求。

市场动态

技术进步将推动神经诊断市场的增长

神经诊断的技术进步大大提高了评估和了解神经系统结构和功能的能力。例如，脑电图使用放置在头皮上的电极测量大脑中的电活动。最近的进展包括高密度脑电图阵列，它有更多的电极，能够更精确地定位大脑活动并提高空间分辨率。

此外，PET成像涉及将放射性示踪剂注入体内，可用于测量大脑中的血流、代谢和特定分子过程。PET成像的最新进展包括开发新型示踪剂，可以针对特定的神经过程或受体，提供对神经化学异常的宝贵见解。因此，技术进步推动了市场增长。

诊断和程序的高成本将阻碍市场的增长

采用成像技术需要大量投资，这些技术的高成本限制了它们的使用，特别是在发展中国家和低收入国家的医疗机构。一台CT扫描仪的成本从35,000美元到100,000美元不等，有些设备的成本要高得多。

另一方面，一台PET扫描仪大约需要250万美元，而一台MRI扫描仪大约需要200万美元。这些费用被认为是过于昂贵，阻碍了市场的采用和扩展。

COVID-19影响分析

由于大流行，许多医疗机构和诊断中心不得不将资源优先用于COVID-19检测和治疗。这导致非紧急的神经诊断服务暂时中止或减少，导致病人的程序和测试被延迟或推迟。COVID-19大流行病对全球的心理健康产生了重大影响。

压力、焦虑和抑郁水平的提高会影响神经功能，可能需要进行额外的神经诊断评估。神经诊断法可以在评估和监测该大流行病对心理健康的神经系统影响方面发挥作用。然而，它也加速了远程医疗和远程监测的采用，为未来改善可及性和病人护理提供了机会。

俄罗斯-乌克兰战争影响分析

俄罗斯-乌克兰战争估计对全球神经诊断学市场的影响很小，因为该地区流行率低，没有关键的市场参与者。然而，在预测期内，原材料、测试产品和设备的进出口的影响预计对全球神经诊断市场的影响很小。

人工智能影响分析

人工智能预计将对全球子痫前期市场产生积极的影响。由于人工智能可以分析个别病人的数据，包括遗传信息、病史和成像结果，以产生个性化的治疗计划。

通过考虑多种因素并根据每个病人的具体需求进行干预，人工智能可以优化治疗效果并减少不良反应。人工智能可以分析患者个人数据，包括遗传信息、病史和成像结果，以生成个性化的治疗计划。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品抽查
  • 按情况分析
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 神经系统疾病的发病率不断上升
      • 技术进步
    • 限制因素
      • 诊断和手术费用高
    • 机会
      • 便携式、可穿戴式和移动式神经诊断设备的发展
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第六章：COVID-19分析

  • 对COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：人工智能影响分析

第九章：按产品分类

  • 诊断和成像系统
    • 计算机断层扫描（CT）扫描仪
    • 脑电图（EEG）系统
    • 位置发射断层扫描（PET）系统
    • 肌电图（EMG）产品
    • 超声波成像系统
    • 脑磁图（MEG）系统
    • 血管造影系统
    • 其他系统
  • 临床检验仪器
    • 聚合酶链反应 (PCR)
    • 下一代测序 (NGS)
    • 桑格测序仪
    • 其他临床诊断产品
  • 试剂和消耗品
    • 酶、蛋白质和多肽
    • 缓冲剂
    • 探针
    • 培养基和血清
    • 溶剂
    • 抗体
    • 其他试剂

第十章：按病情分类

  • 神经退行性疾病
  • 癫痫
  • 中风
  • 头痛症
  • 睡眠障碍
  • 其他

第11章：按终端用户分类

  • 医院和手术中心
  • 非住院护理中心
  • 诊断实验室和影像中心
  • 神经病学中心
  • 其他

第十二章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第13章 ：竞争格局

  • 竞争格局
  • 市场份额分析
  • 合併和收购分析

第十四章：公司简介

  • Hoffman-La Roche AG
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Hitachi Ltd
  • FUJIFILM Holdings Corporation
  • Mitsar Co Ltd
  • Thermo Fischer Scientific Inc
  • Bio-Rad Laboratories
  • QIAGEN NV

第十五章 ：附录

简介目录
Product Code: MD5095

Market Overview

The Global Neurodiagnostics Market reached US$ 7.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 13.2 billion by 2030. The global neurodiagnostics market is expected to exhibit a CAGR of 7.6% during the forecast period 2023-2030.

Neurodiagnostic tests can detect abnormalities in the nervous system at an early stage, even before symptoms become apparent. This early detection allows for timely intervention and treatment, potentially preventing further damage or progression of the condition. Neurodiagnostics can help differentiate between different neurological conditions that may have similar symptoms.

The rising incidence of neurological illnesses such as Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and spinal muscular atrophy will drive demand for neurodiagnostic products over the projected period.

Market Dynamics

Technological Advancements will Drive the Neurodiagnostics Market Growth

Technological advancements in neuro diagnostics have greatly improved the ability to assess and understand the structure and function of the nervous system. For instance, EEG measures electrical activity in the brain using electrodes placed on the scalp. Recent advancements include high-density EEG arrays, which have a larger number of electrodes, enabling more precise localization of brain activity and improved spatial resolution.

Additionally, PET imaging involves injecting a radioactive tracer into the body, which can be used to measure blood flow, metabolism and specific molecular processes in the brain. Recent advancements in PET imaging include the development of novel tracers that can target specific neurological processes or receptors, providing valuable insights into neurochemical abnormalities. As a result, technological advancements drive market growth.

High Cost of Diagnosis and Procedure will Hamper the Market Growth

Adoption of imaging technology involves significant investment and the high cost of these technologies limits their utilisation, particularly in healthcare facilities in developing and low-income nations. The cost of a CT Scanner can range from $35,000 to $100,000, with some devices costing considerably more.

A PET scanner, on the other hand, costs around USD 2.5 million, while an MRI scanner costs around USD 2 million. These sums are seen as prohibitively expensive, impeding market adoption and expansion.

COVID-19 Impact Analysis

Due to the pandemic, many healthcare facilities and diagnostic centers had to prioritize resources for COVID-19 testing and treatment. This resulted in the temporary suspension or reduction of non-urgent neurodiagnostic services, leading to delayed or postponed procedures and tests for patients. The COVID-19 pandemic has had a significant impact on mental health globally.

Increased levels of stress, anxiety, and depression can influence neurological function and may require additional neurodiagnostic evaluations. Neurodiagnostics can play a role in assessing and monitoring the neurological effects of the pandemic on mental health. However, it has also accelerated the adoption of telemedicine and remote monitoring, providing opportunities for improved accessibility and patient care in the future.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global neurodiagnostics market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test products and devices is anticipated to have little influence over the global neurodiagnostics market in the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is anticipated to impact the global preeclampsia market positively . Due to AI can analyze individual patient data, including genetic information, medical history and imaging results, to generate personalized treatment plans.

By considering multiple factors and tailoring interventions to the specific needs of each patient, AI can optimize treatment efficacy and reduce adverse effects. AI can analyze individual patient data, including genetic information, medical history and imaging results, to generate personalized treatment plans.

Segment Analysis

The global neurodiagnostics market is segmented based on product, condition, end user and region.

The Diagnostic & Imaging Systems Segment is Estimated to Hold the Majority of the Neurodiagnostics Market Share During the Forecast Period

The diagnostic & imaging systems product holds about 53.7% of the total neuro diagnostics market in the forecast period. The increasing number of product launches by the key players helps to drive the market.

For instance, on November 28, 2022, Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global pioneer in revolutionary diagnostic imaging technology, announced the release of SP Configurations, Orian SP, and Galan SP. This recent release includes AI-driven workflow solutions, an intelligent Ceiling Camera and the Tablet UX mobile interface, and is intended to deliver high-end performance daily.

And on February 28, Hyperfine, Inc., the pioneering medical device firm that developed the Swoop system, the world's first FDA-cleared portable MRI system, announced the 510(k) clearance of the newest upgrade to its Swoop system software. The category is predicted to grow throughout the projection period as a result of the aforementioned factors.

Geographical Analysis

Europe is Estimated to Hold the Second Largest Share of the Global Neurodiagnostics Market During the Forecast Period

The Europe region holds the second largest share of the global neurodiagnostics market accounting for approximately 27.7% in the forecast period. With the collaborations between major parties rising, as is public awareness of neurological illnesses and brain health. For instance, on December 12, 2022, Natus Medical Inc. secured a contractual contract with Micromed Group SpA, an EU-based provider of neurophysiology solutions.

The transaction is scheduled to close in the first quarter of 2023, subject to regulatory approval from the French Ministry of Economy and Finance and the Italian Council of Ministers Presidency. The goal of this agreement is to provide access to a single portfolio of neuromonitoring and neurodiagnostic equipment to the EU and the rest of the world.

Competitive Landscape

The major global players in the market include: Hoffman-La Roche AG, GE Healthcare, Siemens Healthineers, Philips Healthcare, Hitachi Ltd, Fujifilm Holdings Corporation, Mitsar Co Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories, Qiagen NV, among others.

Why Purchase the Report?

  • To visualize the global neurodiagnostics market segmentation based on product, condition, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of neuro diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Neurodiagnostics Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 pages.

Target Audience 2023

  • Manufacturers / Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Condition
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of neurological diseases
      • 4.1.1.2. Technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of diagnosis and procedure
    • 4.1.3. Opportunity
      • 4.1.3.1. The development of portable, wearable and mobile neurodiagnostic devices
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Impact Analysis

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Diagnostic & Imaging Systems
    • 9.2.1. Computed Tomography (CT) Scanner
    • 9.2.2. Electroencephalogram (EEG) Systems
    • 9.2.3. Position emission tomography (PET) System
    • 9.2.4. Electromyography (EMG) Products
    • 9.2.5. Ultrasound Imaging Systems
    • 9.2.6. Magnetoencephalogram (MEG) System
    • 9.2.7. Angiography System
    • 9.2.8. Other Systems
    • 9.2.9. Introduction
    • 9.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Clinical Testing Instruments
    • 9.3.1. Polymerase Chain Reaction (PCR)
    • 9.3.2. Next Generation Sequencing (NGS)
    • 9.3.3. Sanger Sequencing
    • 9.3.4. Other Clinical Diagnostic Products
  • 9.4. Reagents & Consumables
    • 9.4.1. Enzymes, Protein & Peptides
    • 9.4.2. Buffers
    • 9.4.3. Probes
    • 9.4.4. Media and Serra
    • 9.4.5. Solvents
    • 9.4.6. Antibodies
    • 9.4.7. Other Reagents

10. By Condition

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 10.1.2. Market Attractiveness Index, By Condition
  • 10.2. Neuro Degenerative Disease
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Epilepsy
  • 10.4. Stroke
  • 10.5. Headache Disorder
  • 10.6. Sleep Disorder
  • 10.7. Others

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.1.2. Market Attractiveness Index, By End-User
  • 11.2. Hospital and Surgery Centers
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Ambulatory Care Centers
  • 11.4. Diagnostic Laboratories & Imaging Centers
  • 11.5. Neurology Centers
  • 11.6. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Hoffman-La Roche AG
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. GE Healthcare
  • 14.3. Siemens Healthineers
  • 14.4. Philips Healthcare
  • 14.5. Hitachi Ltd
  • 14.6. FUJIFILM Holdings Corporation
  • 14.7. Mitsar Co Ltd
  • 14.8. Thermo Fischer Scientific Inc
  • 14.9. Bio-Rad Laboratories
  • 14.10. QIAGEN NV

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us